Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.
Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs
Jack Richard
A mutation in a known hereditary breast cancer predisposition gene, such as BRCA1 or BRCA2.1, is linked to between 5% and 10% of the 2.3 million breast cancer cases diagnosed annually2. The integration of genomics into the standard diagnostic pathways for breast cancer patients and the availability of targeted treatment approaches for those with hereditary breast cancer predisposition genes are two examples of the effects that chemotherapy has on breast cancer efficacy. These patients now require a different approach to care than they did a decade ago because of mutations. The most recent advances in systemic treatment for hereditary breast cancer are discussed in this review, as well as the challenges that must be overcome in the future to improve clinical outcomes for this particular subgroup